Financial Performance - Revenue and non-GAAP net profit increased in the first half of the year, but net profit slightly decreased due to the impact of the pandemic [2][3] - Non-recurring gains and losses decreased in the first half, but recovery began in May and is not expected to affect annual performance [2][3] Strategic Partnerships - The strategic cooperation agreement with Mengniu is expected to be renewed for another three years by the end of the year [3] - The company has partnered with Jiangzhong Pharmaceutical and Shangyao Xinyi for its probiotic business [3] Product Development and Market Strategy - The company's Jinhua Galaxy strain factory meets the production conditions for health supplements, and the company has started laying out in this area [3] - The company is focusing on both B2B and B2C markets for its probiotic business, leveraging partnerships with large food and pharmaceutical companies for B2C product development [4] - The company is conducting clinical trials and research to back the efficacy of its probiotic products [4] Operational Details - The company implements a policy of payment before delivery for its probiotic products sold through offline distributors [4] - Some R&D personnel hold shares in the company through partnerships [4] - The Beijing compound food additive factory has a designed single-shift capacity of 3,500 tons, with the ability to increase shifts to meet demand [4] Industry Insights - Developing probiotic strains requires significant investment in time and resources, and internationally recognized strains have undergone extensive research and clinical trials [3][4]

Group 1: Company Overview and Market Position - The company has been focusing on the research and development of probiotics, particularly in the area of Helicobacter pylori, which has gained significant market attention recently [2][3] - Since its establishment, the company has relied on its proprietary strain resources and has conducted over 50 clinical trials in collaboration with top-tier hospitals, with 29 trials completed [3] - The company aims to achieve technological breakthroughs and deliver products that benefit consumers and society [3] Group 2: Product Development and Clinical Trials - The company has identified several key probiotic strains, including Lactobacillus Zhang and Bifidobacterium V9, and has validated their beneficial functions through large-scale clinical trials [3] - The company has expanded into the probiotic pharmaceutical sector since 2019, elevating its research efforts [3] - The focus on Helicobacter pylori will continue, with ongoing product design and research efforts [3] Group 3: Investor Insights and Market Growth - The company believes it is on par with international probiotic companies in terms of research and development, despite starting later [3] - The domestic probiotic market is experiencing rapid growth, with significant market share still held by multinational corporations [3] - As the only publicly listed probiotic company in China, the company is confident in the future growth of its probiotic product segment [3]

北京科拓恒通生物技术股份有限公司 2022 年半年度报告全文 北京科拓恒通生物技术股份有限公司 2022 年半年度报告 2022-057 2022 年 08 月 1 北京科拓恒通生物技术股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘晓军、主管会计工作负责人余子英及会计机构负责人(会计 主管人员)余子英声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划等前瞻性描述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。敬请广大投资者理性投资，注意风险。 公司可能面临的风险详见本报告"第三节 管理层讨论与分析"之"十、 公司面临的风险和应对措施"，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 重要提示、目录和释义 | 2 | ...